DMK Pharmaceuticals

DMK Pharmaceuticals, Inc. was developing a novel second-generation mixed opioid receptor agonist for treatment of moderate-to-severe pain, in transdermal, buccal and oral administration formats.

Merged with Adamis Pharmaceuticals (NASDAQ CM: DMK; 2023).